The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer
Open accessAbstract
Significance: In vitro and in vivo data indicate that hypersialylated tumor cells can engage Siglec-9 on myelomonocytic cells and influence the outcome of the interaction, depending on the stage of tumor growth and the microenvironment. On one hand, engagement of Siglec-9 or Siglec-E by tumor-associated ligands inhibited immunosurveillance and tumor cell killing during establishment of autologous tumors and new metastatic foci. On the other hand, inhibition of tumor-associated macrophages through Siglec-9 led to M1 polarization and reduced growth-promoting inflammation within the tumor microenvironment. This demonstrates a previously unidentified dualistic function of Siglec-9 during cancer progression. A functional polymorphism of Siglec-9 correlated with altered survival of lung cancer patients, suggesting that Siglec-9 might be therapeutically targeted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“Whereas polarization to M1 macrophages enhances tumor cell clearance, polarization to an M2 phenotype supports cancer progression (12, 14).”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 3×
“Discussion Immune cells can either inhibit or support cancer, depending on the microenvironment and phase of disease progression (10, 13).”
BackgroundInfluentialMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 1×
“Whereas polarization to M1 macrophages enhances tumor cell clearance, polarization to an M2 phenotype supports cancer progression (12, 14).”
BackgroundNeutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, J., Spicer, J., McDonald, B., Gowing, S., Chow, S., Giannias, B., Bourdeau, F., Kubes, P., & Ferri, L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67484 · Cited by 1,395
Macrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Tumor entrained neutrophils inhibit seeding in the premetastatic lung
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.012 · Cited by 782
Carlin, A. F., Uchiyama, S., Chang, Y.-C., Lewis, A. L., Nizet, V., & Varki, A. (2009) · Blood · doi:10.1182/blood-2008-11-187302 · Cited by 401 · cited 1×
“We hypothesized that hypersialylated tumor cells inhibit the innate immune system by engaging the predominant Siglec on myelomonocytic cells, Siglec-9, similar to what was recently shown for pathogenic bacteria, such as group B Streptococci, in vitro (4) and in a mouse model in vivo by taking advantage of Siglec-E– de…”
BackgroundSelf-citationVarki, A. (2011) · Glycobiology · doi:10.1093/glycob/cwr087 · Cited by 263
Self-citationLoss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204
Self-citation
Cited by
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Sialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Self-citationSiglecs as Immune Cell Checkpoints in Disease
Duan, S., & Paulson, J. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-102419-035900 · Cited by 452
Precision glycocalyx editing as a strategy for cancer immunotherapy
Xiao, H., Woods, E. C., Vukojicic, P., & Bertozzi, C. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608069113 · Cited by 440
Metadata
- Authors
- Läubli, H., Pearce, O. M. T., Schwarz, F., Siddiqui, S. S., Deng, L., Stanczak, M. A., Deng, L., Verhagen, A., Secrest, P., Lusk, C., Schwartz, A. G., Varki, N. M., Bui, J. D., & Varki, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-09-15
- Volume
- 111
- Issue
- 39
- Pages
- 14211-14216
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2150838615
- Cited by
- 228
- References
- 10
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.